Business Information
The group's principal activity is to discover, develop and commercialize small molecule drugs. These drugs are used in the treatment of viral diseases, cancer, auto immune and inflammatory diseases and neurological disorders. The group has created pipeline using a proprietary approach, information-driven drug design that integrates advanced biology, chemistry, biophysics and information technologies to make drug discovery process more efficient and productive. The group operates in one segment, pharmaceuticals, and all revenues are from U.S. Operations.
|
|
Name |
Title
|
Email
|
| Charles Sanders | Chmn. | N/A | | Amit Sachdev | Sr. VP - Public Policy, Government Affairs | N/A | | Ian Smith | CFO, Exec. VP | N/A | | John Alam | Exec. VP - Medicines Development, Chief Medical Officer | N/A | | Kenneth Boger | Sr. VP, General Counsel | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 216,356 | (206,891) | | 2005 | 160,890 | (203,417) | | 2004 | 102,717 | (166,247)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
